Journals / Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi / 2007 / Cilt: 21 - Sayı: 2

Neuroprotection and neuroprotective agents

Nöroproteksiyon ve nöron koruyucu ajanlar

Pages
119–130
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, it was aimed to present the most recent reports on the studies of neuroprotective agents, which are currently the subject of ongoing research

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The brain is an area where the reversibility of any damage including stroke or concussion is almost impossible.
📊
Key Findings & Data:Most of these agents are small molecules, which can penetrate blood-brain barrier and reach the inner regions of the brain.
💡
Conclusion & Impact:In this review, it was aimed to present the most recent reports on the studies of neuroprotective agents, which are currently the subject of ongoing research
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Nöroprotektif ajanlar · Beyin hasarları · Oksijen azlığı

Abstract

The brain is an area where the reversibility of any damage including stroke or concussion is almost impossible. In recent literature, however, it has been reported that, some agents offer protection against neuronal cell degeneration. Neuroprotection defines the administration of some agents, which should reverse some of the neuronal damage or prevent further damage. Most of these agents are small molecules, which can penetrate blood-brain barrier and reach the inner regions of the brain. Research studies on neuroprotection are currently a comprehensive subject of the field of neuroscience. In this review, it was aimed to present the most recent reports on the studies of neuroprotective agents, which are currently the subject of ongoing research

Özet

Beyin, strok ya da beyin sarsıntısı gibi hasarlanmaların geri dönüşümünün hemen hemen olanaksız olduğu bir bölgedir. Bununla birlikte son yayınlarda bazı ajanların nöronal hücre harabiyetine karşı koruyucu etkilerinin olduğu bildirilmiştir. Nöroproteksiyon ya da nöron koruma, nöronal hasarın bir kısmını geri döndüren ya da daha ileri hasarlanmanın oluşmasını önleyen ajanların uygulanması demektir. Bu ajanların çoğu küçük moleküller olup kan-beyin bariyerini geçerek beynin iç kısımlarına ulaşabilirler. Nöroproteksiyonla ilgili araştırmalar günümüzde nörobilimin üzerinde en kapsamlı olarak durduğu alanlardan biridir. Bu derlemede halen araştırma konusu olan nöroprotektif ajanlarla ilgili son literatür verilerinin derlenerek sunul¬ması amaçlanmıştır

🔖

Cite This Article

KURUL, S., GÜLMEZ, Ö. (2007). Neuroprotection and neuroprotective agents. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, Cilt: 21 - Sayı: 2, 119–130. https://ajindex.com/articles/199464

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Purves D, Augustine GJ, Fitzpatrick D, et al. Neuro-science. Second edition. Massachusetts: Sinauer Asso-ciates Inc, 2001; 471-561
  2. Drian MJ, Bardoul M, Konig N. Blockade of ampa/kainate receptors can either decrease or increase the survival of cultured neocortical cells depending on the stage of maturation. Neurochem Int 2001;38:509-517
  3. Levi MS, Brimble MA. A review of neuroprotective agents. Curr Med Chem 2004;11:2383-2397
  4. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399:7-14
  5. Kırış T, Görgülü A. Eksitatör aminoasitler ve eksito-toksisite. Türk Nöroşirürji Dergisi 2005; 15:39-44
  6. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000;2:85-97
  7. Nozaki, K, Beal MF. Neuroprotective effects of L-kynu-renine on hypoxia-ischemia and NMDA lesions in neo-natal rats. J Cereb Blood Flow Metab 2000;12:400-407
  8. Popovic R, Liniger R, Bickler PE. Anesthetics and mild hypothermia similarly prevent hippocampal neuron death in an in vitro model of cerebral ischemia. Anesthesiology 2000;92:1343-1349
  9. Miura Y, Grocott HP, Bart RD, Pearlstein RD, Dexter F, Warner DS. Differential effects of anesthetic agents on outcome from near-complete but not incomplete global ischemia in the rat. Anesthesiology 1998;89:391-400
  10. Kawaguchi M, Kimbro JR, Drummond JC, Cole DJ, Kelly PJ, Patel PM. Isoflurane delays but does not prevent cerebral infarction in rats subjected to focal ischemia. Anesthesiology 2000;92:1335-1342
  11. Fox C, Dingman A, Derugin N, et al. Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2005;25:1138-1149
  12. Gluckman PD, Wyatt JS, Azzopardi, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 2005;365:663-670
  13. Rutherford MA, Azzopardi D, Whitelaw A, et al. Mild hypothermia and the distribution of cerebral lesions in neonates with hypoxic-ischemic encephalopathy. Pediat-rics 2005;116;1001-1006
  14. Coulborne F, Grooms SY, Zukin RS, et al. Hypothermia rescues hippocampal ca1 neurons and attenueates down-regulation of the ampa receptor glur2 subunit after forebrain ischemia. Proc Natl Acad Sci USA 2003;100: 2906-2910
  15. Jones NM, Berger